Relay Therapeutics (RLAY) Projected to Post Earnings on Thursday

Key Points

• Relay Therapeutics (NASDAQ: RLAY) is set to announce its Q2 2025 earnings on August 5th, with analysts anticipating earnings of ($0.49) per share and revenue of $0.07 million.
• In the last earnings report, Relay Therapeutics reported earnings of ($0.46) per share and revenue of $7.68 million, surpassing estimates by a significant margin.
• The stock has seen a 1.1% decline recently and has a market cap of approximately $634.35 million, reflecting its current position in the market.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $0.07 million for the quarter.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.04. The business had revenue of $7.68 million for the quarter, compared to analysts' expectations of $0.01 million. During the same quarter in the previous year, the business posted ($0.62) earnings per share. Relay Therapeutics's revenue for the quarter was down 23.0% on a year-over-year basis. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Stock Down 4.5%

Shares of RLAY stock traded down $0.16 during trading hours on Friday, hitting $3.36. 2,789,533 shares of the company's stock traded hands, compared to its average volume of 2,643,379. The stock's fifty day simple moving average is $3.42 and its two-hundred day simple moving average is $3.39. Relay Therapeutics has a 12-month low of $1.77 and a 12-month high of $10.72. The stock has a market cap of $576.07 million, a price-to-earnings ratio of -1.51 and a beta of 1.62.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on RLAY shares. Guggenheim lowered their target price on shares of Relay Therapeutics from $30.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company began coverage on shares of Relay Therapeutics in a report on Thursday, April 17th. They issued an "equal weight" rating and a $4.00 price objective for the company. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $17.67.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, CEO Sanjiv Patel sold 61,379 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $3.57, for a total transaction of $219,123.03. Following the completion of the sale, the chief executive officer directly owned 765,288 shares in the company, valued at approximately $2,732,078.16. The trade was a 7.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Bergstrom sold 26,701 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $3.68, for a total transaction of $98,259.68. Following the sale, the insider owned 552,720 shares of the company's stock, valued at approximately $2,034,009.60. This represents a 4.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 149,226 shares of company stock worth $542,926. 4.87% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its stake in shares of Relay Therapeutics by 14.6% in the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company's stock worth $7,710,000 after purchasing an additional 374,491 shares in the last quarter. Woodline Partners LP increased its stake in shares of Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company's stock worth $3,979,000 after purchasing an additional 1,241,657 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Relay Therapeutics by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company's stock worth $956,000 after purchasing an additional 38,812 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Relay Therapeutics by 47.6% in the 1st quarter. Jane Street Group LLC now owns 111,472 shares of the company's stock worth $292,000 after purchasing an additional 35,962 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Relay Therapeutics by 6.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company's stock worth $221,000 after purchasing an additional 5,238 shares in the last quarter. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.